Gremlin 2 is Repressed in Invasive Endometrial Cancer and Inhibits Cell Growth In Vitro

There exist limited therapeutic opportunities regarding the treatment of endometrial cancer (EC), and novel therapies based on the molecular profiling of EC cells are required. We used microarray analysis of EC tumour samples in order to identify tumour-specific changes regarding gene expression. It...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2016-01, Vol.36 (1), p.199
Main Authors: Tsubamoto, Hiroshi, Sakata, Kazuko, Sakane, Riya, Inoue, Kayo, Shibahara, Hiroaki, Hao, Hiroyuki, Hirota, Seiichi
Format: Article
Language:English
Subjects:
Cell Movement
Cell Proliferation
Endometrial Neoplasms - immunology
Endometrial Neoplasms - pathology
Female
Humans
In Vitro Techniques
Intercellular Signaling Peptides and Proteins - metabolism
Signal Transduction
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There exist limited therapeutic opportunities regarding the treatment of endometrial cancer (EC), and novel therapies based on the molecular profiling of EC cells are required. We used microarray analysis of EC tumour samples in order to identify tumour-specific changes regarding gene expression. It was found that gremlin 2, an inhibitor of bone morphogenetic protein (BMP) signaling, was repressed in EC samples, and that gremlin 2 inhibited tumour cell growth. Down-regulation of gremlin 2 may lead to carcinogenesis and progression of EC. We suggest that re-activation of gremlin 2-associated pathways could suppress EC progression and should thus be explored as a potential novel therapeutic approach.
ISSN:1791-7530